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Abnormalities of the basal ganglia are frequently seen in HIV-infected (HIV+) children
despite antiretroviral treatment (ART) initiation during childhood. Assessment of
metabolites associated with neuronal integrity or with glial proliferation can present a
sensitive description of metabolic events underlying basal ganglia structural changes.
We used magnetic resonance spectroscopy to examine differences in creatine, choline,
N-acetylaspartate (NAA), glutamate, and myo-inositol between HIV+ children and HIV-
unexposed controls, as well as between HIV-exposed uninfected (HEU) children and
HIV-unexposed controls at age 7 and at age 9. No differences in metabolites relative to
the HIV-unexposed control group were found at age 7. However, at 9 years, both HIV+
and HEU had lower NAA and glutamate than unexposed control children. HEU children
also had lower creatine and choline than control children. At age 7, lower CD4/CD8
ratio at enrollment was associated with lower choline levels. At age 9 lower CD4/CD8
at enrollment was associated with lower myo-inositol. Low NAA and glutamate at
age 9, but not 7, suggest that basal ganglia neurons may be particularly affected by
perinatal HIV/ART and that neuronal damage may be ongoing despite early ART and
viral suppression. Reduced basal ganglia metabolite levels in HEU children suggest an
effect of HIV exposure on childhood brain development that merits further investigation
using neuroimaging and neurocognitive testing.
Keywords: HIV, early ART initiation, NAA, glutamate, magnetic resonance spectroscopy, basal ganglia, HIV
exposure
INTRODUCTION
Although infants with perinatal HIV infection can now expect to survive childhood, they face
life-long treatment with antiretrovirals (ARVs) in order to maintain a healthy immune system.
Starting antiretroviral therapy (ART) before 3 months of age yields good clinical, immunological,
and developmental outcomes (Violari et al., 2008; Laughton et al., 2012; Cotton et al., 2013;
Frontiers in Human Neuroscience | www.frontiersin.org 1 May 2018 | Volume 12 | Article 145
fnhum-12-00145 May 3, 2018 Time: 17:34 # 2
Robertson et al. Altered Neurometabolism in HIV-Infected Children
Crowell et al., 2015). However, it is known that ART cannot
completely reverse the neurological effects of HIV (Laughton
et al., 2013; van Arnhem et al., 2013; Whitehead et al., 2014) and
neurodevelopmental delay and neurocognitive deficits remain
(Govender et al., 2011; Donald et al., 2014; Wilmshurst et al.,
2014; Musielak and Fine, 2015). In addition, neurotoxic effects
of ART itself (Robertson et al., 2012) may be detrimental to brain
development.
Abnormalities of the basal ganglia are frequently seen in
HIV-infected (HIV+) children and adults (George et al., 2009;
Hoare et al., 2014), and subcortical structures may contain the
highest levels of the virus (Tornatore et al., 1994). Neuroimaging
shows that HIV+ children may have shape and volume
alterations in subcortical gray matter (Lewis-de los Angeles et al.,
2016; Yadav et al., 2017) and calcification of the basal ganglia
(Govender et al., 2011), despite ART initiation during childhood.
Magnetic resonance spectroscopy (MRS) measures brain
metabolites including creatine (Cr), involved in energy
metabolism, N-acetyl-aspartate (NAA), reflecting neuronal
integrity, and glutamate (Glu), the primary excitatory
neurotransmitter, as well as choline (Cho) and myo-Inositol
(Ins). Ins is considered a glial marker and Cho reflects cell
membrane turnover – both present in larger concentrations in
glial cells than in neurons. Assessment of metabolites associated
with neuronal integrity — NAA and Glu, and those associated
with glial proliferation — Ins and Cho, can present a sensitive
description of metabolic events underlying, and even preceding,
the structural changes in basal ganglia seen in HIV+ children.
Early single voxel spectroscopy (SVS) studies in children
with HIV encephalopathy (HIVE) found lower NAA/Cr ratios
in the basal ganglia compared to HIV+ children without
encephalopathy and controls (Pavlakis et al., 1995; Lu et al.,
1996). In earlier studies where most HIV+ children did not
have encephalopathy, no alterations in basal ganglia NAA
were found (Lu et al., 1996; Keller et al., 2004; Prado et al.,
2011). More recently, Mbugua et al. (2016) reported higher
absolute NAA levels in HIV+ children initiating ART before
12 weeks compared to a control group comprising mostly (80%)
HIV-exposed uninfected (HEU) children.
Findings on glial metabolites in the basal ganglia are less
consistent. Keller colleagues and Lu colleagues found lower Cho
(Keller et al., 2004) and Cho/Cr (Lu et al., 1996) in HIV+
children than controls. However, other studies found higher
basal ganglia Cho/Cr (Ashby et al., 2015) and Ins/Cr (Ashby
et al., 2015) in HIV+ children, as well as higher absolute Cho
(Mbugua et al., 2016) in HIV+ children who started ART before
12 weeks compared to children who initiated treatment later and
a predominantly HEU control group.
Although earlier studies do not report ART use (Pavlakis
et al., 1995; Lu et al., 1996), basal ganglia neurometabolite
alterations reported subsequently were observed even in HIV+
children on ART (Keller et al., 2004; Gabis et al., 2006; Ashby
et al., 2015; Mbugua et al., 2016). However, these studies used
relatively small sample sizes (between 8 and 45 HIV+ subjects)
spanning a wide age range and starting ART at varying stages of
childhood. One study examined basal ganglia neurometabolites
in young children who all initiated ART before 18 months of
age (Mbugua et al., 2016). In that study, lower CD4/CD8 ratio
at enrollment, aged 6–8 weeks, was associated with lower basal
ganglia NAA and Cho at age 5 years, despite early ART initiation
and viral load suppression.
The aim of this study was to investigate whether immune
system impairment in infancy remains associated with lower
NAA and Cho in the basal ganglia at age 7 and at age 9 in an
expanded group from the same cohort studied by Mbugua et al.
(2016). Because increased basal ganglia Cho and NAA in HIV+
children who initiated ART before 12 weeks was attributed to
the use of primarily HEU controls (Mbugua et al., 2016), we
aimed to compare HIV+ children to HIV-unexposed controls. In
addition, although some studies report neurocognitive deficits in
HEU children (Van Rie et al., 2008; Kerr et al., 2014), none have
investigated the effects of perinatal HIV and ART exposure on
neurometabolite levels in childhood. Our second aim therefore,
was to investigate differences in basal ganglia neurometabolite
levels between HEU and HIV-unexposed children (controls) at
ages 7 and 9.
MATERIALS AND METHODS
Participants
Participants included 78 HIV+ children from the Children
with HIV Early Antiretroviral therapy (CHER) trial (Violari
et al., 2008; Cotton et al., 2013) and 53 HIV-uninfected (HIV-)
children from the same community enrolled in a longitudinal
neuroimaging study (Holmes et al., 2017) in Cape Town,
South Africa.
On the CHER trial, infants with CD4+ percentage (CD4%)
of at least 25% were randomized to begin ART early (before
12 weeks of age) and have treatment interrupted after either 40
or 96 weeks, or to have ART deferred until CD4% < 20% (25% in
the first year) or on presentation of clinical symptoms of disease.
A small group with CD4% < 25% were randomized to the early
treatment arms only.
The first line ART regimen consisted of Zidovudine (ZDV)
+ Lamivudine (3TC) + Lopinavir-Ritonavir (LPV/r, Kaletra R©)
(Violari et al., 2008; Cotton et al., 2013). All HIV+ children
started ART before 76 weeks of age and received regular clinical
and immunological follow-up. All but nine children had plasma
HIV RNA below detectable limits (<400 RNA copies/mL) by
2 years of age.
The HIV- children, comprising both unexposed (control)
children born to HIV-seronegative mothers (N = 32) and HEU
children (N = 21) born to HIV+ mothers, were recruited
from a linked vaccine trial (Madhi et al., 2010). HEU children
were exposed to treatment for prevention of mother-to-child
transmission (PMTCT), mostly zidovudine antenatally from 28
to 34 weeks and a single dose of nevirapine (NVP) to the mother
and zidovudine for a week and a single dose of NVP to the infant.
Neuroimaging
Neuroimaging was performed without sedation according
to protocols approved by the Human Research Ethics
Committees of the Universities of Cape Town and Stellenbosch.
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Parents/guardians provided written informed consent and
children provided oral assent. A senior radiologist reviewed all
structural scans, and children with abnormalities were excluded
from analysis.
At 7 years, children were scanned on a 3T Allegra MRI scanner
(Siemens, Erlangen, Germany) using a single channel head coil.
At 9 years, a 3T Siemens Skyra MRI scanner with a 32-channel
head coil was used.
On both scanners, the protocol included a high-resolution
T1-weighted multiecho magnetisation prepared rapid gradient
echo acquisition (MEMPRAGE; Van der Kouwe et al., 2008)
FOV 224 mm × 224 mm, TR 2530 ms, TI 1160 ms,
TE’s = 1.53/3.19/4.86/6.53 ms, bandwidth 650 Hz/px, 144 slices,
1.3 mm× 1.0 mm× 1.0 mm) and single voxel 1H-MRS (PRESS:
1.5 cm × 1.5 cm × 1.5 cm voxel; TR 2000 ms, TE 30 ms,
64 averages) in the basal ganglia with Chemical Shift Selective
(CHESS) water suppression. A water reference was acquired in
the same voxel without water suppression. On the Allegra, an EPI
volumetric navigated (vNav) PRESS (Hess et al., 2011) sequence
was used that applies prospective motion- and shim correction
throughout the acquisition and has been shown to provide high
quality repeatable spectra in young children (Hess et al., 2013).
The basal ganglia voxel comprised approximately 60% gray
matter and anatomically represents the frontal limb of the
internal capsule and part of the caudate nucleus, putamen,
and globus pallidus (representative voxel placement shown in
Figure 1). Shimming was performed over the voxel volume, first
automatically using the scanner’s “Advanced” adjustment, then
manually if necessary to reduce the spectral linewidths reported
by the scanner.
LCModel (Provencher, 2001) was used to perform eddy
current correction and to calculate metabolite ratios to creatine,
as well as absolute concentrations using the water scaling
method (Ernst et al., 1993; Kreis et al., 1993). SPM12
software was used to segment the MEMPRAGE regions
corresponding to the SVS voxel into gray matter, white matter,
and cerebrospinal fluid (CSF) for partial volume correction and
water concentration calculation. Spectra were eliminated if the
quality was poor (signal-to-noise ratio < 7, line width at half
the peak maximum > 0.07 parts per million as reported by
LCModel).
Statistical Analysis
Because metabolite levels are scanner-dependent and measured
in institutional units, data from scans at different ages were
treated independently with separate cross-sectional analyses at
each age, to examine differences in Cr, Cho, NAA, Glu, and
Ins between HIV+/HEU children and HIV-unexposed controls.
Linear regression models in the R programming language (R
Core Team, 2013) were used, with age at scan, gender, ethnicity,
and voxel gray matter content as confounders. To ensure that
results were not driven by influential outliers, all analyses were
repeated excluding concentration estimates removed more than
1.5 times the interquartile range from the median value for that
metabolite.
In the HIV+ group we also used linear regression analysis to
examine the relationship of metabolite levels to clinical measures
including CD4% at enrollment, CD4/CD8 ratio at enrollment,
CD4% closest to scan and incidence of CDC stage C HIV disease.
RESULTS
At age 7, spectra from 17 HIV+ (38%), 6 HEU (43%), and 7
control children (33%) did not meet the quality control criteria
and were excluded. At age 9, data from 1 HIV+ child were
excluded. Scans from 37 HIV+ children, 10 HEU children and
13 control children provided data at both 7 and 9 years. Figure 1
shows the voxel placement and example basal ganglia spectra
from the Allegra and Skyra scanners.
Demographic data for subjects included at age 7 and age 9
are presented in Table 1. At age 7 there was no difference in
birth weight or age between groups. At the 9-year scan there
was no difference in birth weight between groups, but the HIV+
FIGURE 1 | Sample spectrum of median SNR and LCModel output from (A) the Allegra scanner used for the 7 year olds (SNR = 8) and (B) the Skyra scanner used
for the 9 year olds (SNR = 14). Basal ganglia voxel placement shown in center panel.
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children were younger than the control (p = 0.0003) and HEU
(p = 0.00004) children.
Clinical data for the HIV+ children are presented in Table 2.
Plasma HIV RNA was undetectable (<400 copies/mL) in 91% of
the children (all except 4) at the 7-year and 97% (all except 2) at
the 9-year scan. At the 7-year scan 3 children had not yet restarted
ART after interruption, but by the 9-year scan all children were
on ART.
No differences in metabolites relative to the control group
were found at age 7 (Table 3). However, at 9 years, both
HIV+ and HEU had lower NAA and Glu than control children
(Figure 2 and Table 3). HEU children also had lower Cr and Cho
than control children.
There was no relationship between CD4% at enrollment and
neurometabolites at age 7 or 9 years (Table 4 and Supplementary
Table 1). However, at age 7, lower CD4/CD8 ratio at enrollment
was associated with lower Cho levels. Also, there was a weak
association between lower CD4% at scan and NAA. The same
relationships were not evident at age 9, but at this age lower
CD4/CD8 at enrollment was associated with lower Ins, and a
CDC stage C diagnosis showed a trend-level association with
lower NAA and higher Ins. Relationships of CD4/CD8 ratio at
enrollment to Cho at ages 7 and 9 are illustrated in Figure 3.
DISCUSSION
This study presents SVS basal ganglia neurometabolite data in a
larger sample of older HIV+ children than previously studied,
91% of whom had undetectable viral loads at 7 and 97% at
9 years, and all of whom had started ART before 76 weeks of age.
Although we find no neurometabolite differences at age 7, lower
NAA and Glu is apparent at age 9.
Contrary to findings in a subset of the same children at age 5
(Mbugua et al., 2016), we do not find an effect of immune health
in infancy on basal ganglia NAA at either 7 or 9 years, suggesting
that subsequent health, or other events during childhood, have
a stronger influence on neuronal integrity at these older ages.
However, as at age 5, higher CD4/CD8 ratio at enrollment
remains associated with higher basal ganglia Cho at age 7,
suggesting the effect of early immune health on glial cells may
persist for some time.
TABLE 1 | Biographical data for HIV+, HIV-exposed uninfected (HEU), and
HIV-unexposed uninfected controls scanned at 7 and 9 years.
Age 7 (N = 80) HIV+ (45) HEU (14) Control (21)
Sex 18 M (40%) 7 M (50%) 11 M (52%)
Age (years) 7.20 ± 0.10 7.22 ± 0.10 7.25 ± 0.16
Birth weight (grams) 2970 ± 437 3096 ± 532 3055 ± 382
Age 9 (N = 103) HIV+ (67) HEU (15) Control (21)
Sex 32 M (48%) 9 M (60%) 10 M (47%)
Age (years) 9.27 ± 0.24 9.73 ± 0.53 9.62 ± 0.54
Birth weight (grams) 3071 ± 408 3159 ± 459 3153 ± 358a
Values are mean ± standard deviation. aData missing for 1 subject.
TABLE 2 | Clinical data for HIV+ children scanned at 7 and 9 years.
Age 7 (N = 45) Age 9 (N = 67)
Enrolment data
CD4 (cells/mm3) 1676 ± 897 1928 ± 838
CD4% 33.0 ± 11.6 35.5 ± 8.7
CD4/CD8 1.3 ± 0.7 1.4 ± 0.7a
Plasma viral load
High (>750,000 copies/mL) 26 (58%) 36 (54%)
Low (400–750,000 19 (42%) 31 (46%)
copies/mL) Suppressed
(<400 copies/mL)
0 0
At scan dataa
CD4 (cells/mm3) 1194 ± 507 1067 ± 410
CD4% 36.7 ± 5.8 38.2 ± 7.0
Plasma viral load
High (>750,000 copies/mL)
Low (400–750,000
0 4 (9%) 0 2 (3%)
copies/mL) Suppressed
(<400 copies/mL)
41 (91%) 65 (97%)
Treatment-related data
Age at ART initiation 14.9 ± 13.0 15.1 ± 14.2
(weeks) range 6.6–64.3 range 5.9–75.7
Children on interrupted ART 24 (53%) 37 (55%)
Age at interruption (weeks) 70.5 ± 27.3 72.1 ± 28.1
Duration of interruption Median 35.3 (24.8) Median 34.6 (27.7)
(weeks) Range 5.7–277.9 Range 6.0–398.0
Cumulative time on ART
(weeks)
326.1 ± 64.1 425.9 ± 83.9 weeks
Age at first PVL
suppression
Median 47.0 (57.8) Median 41.4.3 (32.3)
(weeks) Range 30.7–285.6 Range 29.1–213.3
Incidence of virological
breakthrough
28 (62%) 46 (69%)
CDC classification
A 5 (11%) 7 (10%)
B 7 (16%) 10 (15%)
Severe B 9 (20%) 12 (18%)
C 24 (53%) 37 (55%)
HIV encephalopathy cases 8 (13%) 6 (8%)
Values are number (percentage of group), mean ± standard deviation, or median
(interquartile range) and range when specified. Age and duration of interruption
data only for children with treatment interruption. CDC classification data missing
for 1 subject. aMedian interval 63 days from 7 year scan; median interval 22 days
from 9 year scan.
The p-values presented here should, however, be interpreted
with caution, as due to the number of statistical tests the
family-wise error rate is greater than 5%. Findings significant
at p < 0.05 would not have survived correction for multiple
comparisons. Although the observed associations may therefore
represent type I errors, they nevertheless present a starting point
for investigation in future studies.
Decreased NAA and Glutamate in HIV+
Children at Age 9
Similar to previous findings in children without HIVE, at age
7 we find no differences in NAA or other metabolites between
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TABLE 3 | Unstandardised regression coefficients (B), standard error and p-values for basal ganglia absolute metabolite levels relative to control children at age 7 and 9,
controlling for sex, age at scan, ethnicity, and voxel gray matter content.
Age 7 (N = 80) Age 9 (N = 103)
HIV+ (N = 45) HEU (N = 14) HIV+ (N = 67) HEU (N = 15)
B SE p B SE p B SE p B SE p
NAA 0.05 0.11 0.63 0.04 0.15 0.79 −0.25 0.12 0.04 −0.39 0.16 0.02
Glu 0.21 0.24 0.39 0.26 0.31 0.41 −0.46 0.21 0.04 −0.75 0.28 0.008
Cho 0.03 0.03 0.41 0.07 0.04 0.11 0.03 0.03 0.37 −0.10 0.04 0.02
Ins 0.10 0.18 0.59 −0.17 0.23 0.46 −0.14 0.15 0.35 −0.18 0.19 0.35
Cr 0.12 0.13 0.40 0.25 0.17 0.10 −0.12 0.11 0.30 −0.42 0.15 0.005
Coefficients significant at p < 0.05 marked in bold font.
HIV+ children and controls. Although NAA/Cr levels have
been shown to be decreased in basal ganglia in children with
HIVE (Pavlakis et al., 1995; Lu et al., 1996), in HIV+ children
without encephalopathy NAA levels have been reported to
remain unchanged (Keller et al., 2004). In our own previous study
of the same cohort at age 5 years, children who initiated ART
before 12 weeks had higher NAA and choline compared to the
uninfected group of which 80% were HIV exposed (Mbugua et al.,
2016). Notably, at age 9 we find lower NAA and Glu (but not
NAA/Cr or Glu/Cr, Supplementary Table 2) in HIV+ children,
FIGURE 2 | Plots of basal ganglia NAA and glutamate at age 7 and 9 showing mean, 95% confidence intervals and differences in group means significant at
p < 0.05.
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even though only six children in our 9-year old HIV+ group had
a prior HIVE diagnosis.
The reason these differences in NAA and Glu are not observed
at age 7 may be that the normal age-related increase in NAA
(Holmes et al., 2017) is altered in HIV (Keller et al., 2004), such
that NAA is no different from controls at age 7 but has dropped
below control levels by age 9. At age 5 (Mbugua et al., 2016), only
two of the uninfected children were HIV-unexposed, and the rest
HEU, so that we cannot say with any certainty how NAA levels in
HIV+ children compared to those of HIV-unexposed children at
age 5. This makes it difficult to interpret these findings.
No previous study has reported reduced basal ganglia Glu
in HIV+ children; together with reduced NAA this suggests
neuronal cell loss. Neurons in the basal ganglia may be more
vulnerable than other regions to damage via excitotoxicity
because of their greater density of NDMA receptors (Lipton et al.,
1991) or because of increased blood–brain barrier damage in
these structures associated with high plasma viral load (Avison
et al., 2004).
Although in basal ganglia both lower (Lu et al., 1996; Keller
et al., 2004) and higher (Ashby et al., 2015) Cho/Cr and Cho have
previously been found in HIV+ children, we found no difference
in basal ganglia Cho between HIV+ children and controls at
either age. In adults, elevated basal ganglia Cho/Cr normalizes
after ART (Sailasuta et al., 2012). In these children, ART may
have caused normalization of basal ganglia Cho levels, without
preventing cell loss. However, the strongest neurometabolite
effect observed in regressions with clinical data (B/SE, Table 4),
is that of Cho at 7 years against CD4/CD8 at enrollment. This
replicates the finding in the same cohort at age 5 (Mbugua et al.,
2016), suggesting that better immune health in infancy may be
associated with a greater cell density in childhood. Although the
regression coefficient for Cho is 20 times smaller by 9 years of
age, at 9 years the regression coefficient for Ins against baseline
CD4/CD8 is similarly large.
An alternative reason for the lack of group differences at age 7
may be the lower SNR obtained from the single channel head coil
on the Allegra scanner, resulting in higher standard deviations
for metabolite concentrations estimated with LCModel at age 7,
even though spectra still met strict quality control criteria. The
standard errors for the regressions at each age were comparable,
showing similar between-subject variability on each scanner.
However, effect sizes were much larger in the 9 year old data
(Table 3), suggesting greater sensitivity to detect differences on
the Skyra. It is notable, however, that no group differences were
found at age 7 even when regressions were weighted by the
inverse of the metabolite standard deviations, to provide heavier
weighting to metabolite concentrations estimated with greater
precision by LCModel. Moreover, in our study on the same
cohort at age 5 years, we were able to detect in data from the same
scanner, with similar spectra of similar quality, and in a smaller
sample, metabolite differences between HIV+ children initiating
ART before and after 12 weeks (Mbugua et al., 2016).
Alterations in NAA and Glu observed at age 9, but not 5
and 7, suggest that basal ganglia neurons may be particularly
affected by perinatal HIV/ART and that neuronal damage may be
ongoing in this region despite early ART and viral suppression.
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FIGURE 3 | Plots showing a positive relationship between choline and CD4/CD8 ratio at age 7 (B = 0.0521, SE = 0.02, p = 0.01) and none at age 9 (B = 0.0026,
SE = 0.07, p = 1.0). Triangle denotes an influential outlier excluded from statistical analysis.
The results should be considered exploratory, and suggest that
longitudinal investigation should be performed to clarify the
timing and persistence of these effects during childhood.
Reduced Neuronal and Glial
Neurometabolites in HEU Children at
Age 9
Surprisingly, at age 9 we detect reductions in several
neurometabolites in HEU children relative to controls. Notably,
regression coefficients for NAA, Glu, and Cr suggest larger
reductions in HEU than HIV+ children, and a reduction
in Cho is seen relative to controls in HEU but not HIV+
children. Although few neuroimaging studies have been done
in HEU children, one diffusion tensor imaging (DTI) study in
infants identified a region with high fractional anisotropy in
the cerebellum (Tran et al., 2016) and another did not detect
DTI or brain volume differences between HEU and control
children (Jahanshad et al., 2015). Ours is the first to demonstrate
neurometabolite alterations related to HIV/ART exposure. One
previous study found elevated white matter Cho/Cr and NAA/Cr
ratios in neonates exposed to HIV and ART in utero, however,
the HIV status of these infants was not determined (Cortey et al.,
1994).
Although at age 9 HIV+ children on ART show no difference
in Cho level to control children, in HEU children Cho levels are
lowered, suggesting that cell density may be reduced. In addition,
we found reduced Cr, reflecting lowered energy metabolism,
as well as reduced NAA and Glu, possibly reflecting loss of
neurons or reduction in normal neurotransmission. Together,
these neurometabolite reductions support the suggestion of loss
of both neuronal and glial cells.
It is not clear why HIV exposure should be associated
with greater basal ganglia neurometabolite reductions
than HIV infection. It is likely that in the context of
this study HEU children experience some of the same
environmental and social stressors as HIV+ children,
as well as nutritional and health challenges, but do not
have access to the same level of clinical care as the HIV+
children under follow-up on the CHER trial. This may have
resulted in poorer neurodevelopmental outcomes for HEU
children.
Concern has also been raised about mitochondrial dysfunction
in HEU children due to in utero and postpartum exposure
to ARVs, particularly Zidovudine (Poirier et al., 2003), which
may affect neurodevelopment. Neuroimaging in ART-exposed
children without symptoms may show abnormalities similar to
those in children with congenital mitochondrial disease (Tardieu
et al., 2005). Reassuringly, however, the Surveillance Monitoring
for ART Toxicities (SMARTT) cohort of the Pediatric HIV/AIDS
Cohort Study, including more than 3500 children, recently found
no association between in utero exposure to ART drugs and
cognitive or academic scores in school-age children (Van Dyke
et al., 2016).
Although most studies in HEU children under 3 years of
age found no neurodevelopmental differences to controls when
confounding factors were controlled (Alimenti et al., 2006;
Gómez et al., 2009; Williams et al., 2010; Springer et al., 2012;
Ngoma et al., 2014), studies from resource-limited settings
suggest that HEU infants in Africa demonstrate subtle cognitive
and motor impairment, and expressive language delay (Boivin
et al., 1995; Le Doare et al., 2012).
Similarly, studies of school-aged HEU children demonstrate
subtle deficits compared to control children, particularly in
language-related cognitive performance (Van Rie et al., 2008;
Kerr et al., 2014; Milligan and Cockcroft, 2017). A recent
longitudinal study reported that neurodevelopment of HEU
children is initially similar to their HIV-unexposed peers,
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but neurocognitive performance starts to fall behind that of
HIV-unexposed children during childhood (Smith et al., 2017).
This might correspond to a lack of normal age-related increase
in Cho, Glu, and NAA in the basal ganglia during childhood
(Holmes et al., 2017), which could explain our observations of
reduced levels relative to control children at age 9.
It is, however, notable that a recent longitudinal study in the
same cohort showed no differences in linear metabolite change
between HEU and controls between 5 and 10 years, using a
smaller sample of 9-year-old children scanned on a different
scanner a few months earlier (Holmes et al., 2017). A limitation of
the current study is that data were acquired on different scanners
at each age, which does not allow straightforward examination
of change in metabolites with age. The cross-sectional analyses
presented here suggest that the neurometabolite increase with age
may not be linear in one or both of these groups, with a difference
manifesting only at the later end of this age range in the basal
ganglia.
Future work should investigate the association of basal ganglia
metabolites with cognitive performance. Although the basal
ganglia are critically involved in motor control, they are also
implicated in language processing (Booth et al., 2007). It would be
interesting to determine whether basal ganglia neurometabolite
alterations are related to subtle cognitive and language deficits in
HEU children.
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